GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RBC Bioscience Corp (ROCO:6848) » Definitions » EBIT

RBC Bioscience (ROCO:6848) EBIT : NT$17.9 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is RBC Bioscience EBIT?

RBC Bioscience's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was NT$10.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$17.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. RBC Bioscience's annualized ROC % for the quarter that ended in Dec. 2023 was 2.00%. RBC Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3.42%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. RBC Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.77%.


RBC Bioscience EBIT Historical Data

The historical data trend for RBC Bioscience's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RBC Bioscience EBIT Chart

RBC Bioscience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 19.04 178.53 42.28 12.49 17.88

RBC Bioscience Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.20 14.12 -1.63 7.85 10.03

Competitive Comparison of RBC Bioscience's EBIT

For the Biotechnology subindustry, RBC Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RBC Bioscience's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RBC Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where RBC Bioscience's EV-to-EBIT falls into.



RBC Bioscience EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$17.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RBC Bioscience  (ROCO:6848) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

RBC Bioscience's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=16.948 * ( 1 - 17.9% )/( (691.727 + 697.81)/ 2 )
=13.914308/694.7685
=2.00 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=763.194 - 27.198 - ( 66.967 - max(0, 100.418 - 144.687+66.967))
=691.727

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

RBC Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=20.056/( ( (547.266 + max(41.118, 0)) + (533.543 + max(49.338, 0)) )/ 2 )
=20.056/( ( 588.384 + 582.881 )/ 2 )
=20.056/585.6325
=3.42 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(23.438 + 45.015 + 9.267) - (27.198 + 0 + 9.404)
=41.118

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(23.002 + 44.423 + 6.914) - (15.532 + 0 + 9.469)
=49.338

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

RBC Bioscience's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=17.875/644.675
=2.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RBC Bioscience EBIT Related Terms

Thank you for viewing the detailed overview of RBC Bioscience's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


RBC Bioscience (ROCO:6848) Business Description

Traded in Other Exchanges
N/A
Address
Lane 235, Baoqiao Road, 3rd Floor, No. 132, New Taipei City, TWN, 23145
RBC Bioscience Corp is a bio sciences company. Its products include Real Genomics, MagCore Automated Nucleic Acid Extractor, and MagCore Nucleic Acid Extraction KIT.

RBC Bioscience (ROCO:6848) Headlines

No Headlines